Cargando…
A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer
SIMPLE SUMMARY: ASCT2 is an attractive tumour metabolism target based on its critical role in cancer cell growth. The potential mechanisms of microtubule protein inhibitor C118P in breast cancer remain unknown. Identification of the potential target of C118P is essential. We evaluated the inhibitory...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605716/ https://www.ncbi.nlm.nih.gov/pubmed/37894450 http://dx.doi.org/10.3390/cancers15205082 |
_version_ | 1785127144885583872 |
---|---|
author | Lyu, Xiao-Dan Liu, Yang Wang, Jia Wei, Yuan-Cheng Han, Yi Li, Xue Zhang, Qian Liu, Zheng-Rui Li, Zheng-Zheng Jiang, Jing-Wei Hu, Hao-Lin Yuan, Sheng-Tao Sun, Li |
author_facet | Lyu, Xiao-Dan Liu, Yang Wang, Jia Wei, Yuan-Cheng Han, Yi Li, Xue Zhang, Qian Liu, Zheng-Rui Li, Zheng-Zheng Jiang, Jing-Wei Hu, Hao-Lin Yuan, Sheng-Tao Sun, Li |
author_sort | Lyu, Xiao-Dan |
collection | PubMed |
description | SIMPLE SUMMARY: ASCT2 is an attractive tumour metabolism target based on its critical role in cancer cell growth. The potential mechanisms of microtubule protein inhibitor C118P in breast cancer remain unknown. Identification of the potential target of C118P is essential. We evaluated the inhibitory effects of C118P on breast cancer. C118P restrained the tumour growth of MDA-MB-231 cells by inducing apoptosis, G2/M phase arrest, and autophagy. Furthermore, ASCT2 was confirmed to be a target of C118P. This is the first report to provide evidence that ASCT2 might be a candidate target of C118P in breast cancer treatment. Remarkably, this study will provide an opportunity for ASCT2 inhibition as a therapeutic strategy. ABSTRACT: Background: The microtubule protein inhibitor C118P shows excellent anti-breast cancer effects. However, the potential targets and mechanisms of C118P in breast cancer remain unknown. Methods: Real-time cellular analysis (RTCA) was used to detect cell viability. Apoptosis and the cell cycle were detected by flow cytometry. Computer docking simulations, surface plasmon resonance (SPR) technology, and microscale thermophoresis (MST) were conducted to study the interaction between C118P and alanine-serine-cysteine transporter 2 (ASCT2). Seahorse XF technology was used to measure the basal oxygen consumption rate (OCR). The effect of C118P in the adipose microenvironment was explored using a co-culture model of adipocytes and breast cancer cells and mouse cytokine chip. Results: C118P inhibited proliferation, potentiated apoptosis, and induced G2/M cell cycle arrest in breast cancer cells. Notably, ASCT2 was validated as a C118P target through reverse docking, SPR, and MST. C118P suppressed glutamine metabolism and mediated autophagy via ASCT2. Similar results were obtained in the adipocyte–breast cancer microenvironment. Adipose-derived interleukin-6 (IL-6) promoted the proliferation of breast cancer cells by enhancing glutamine metabolism via ASCT2. C118P inhibited the upregulation of ASCT2 by inhibiting the effect of IL-6 in co-cultures. Conclusion: C118P exerts an antitumour effect against breast cancer via the glutamine transporter ASCT2. |
format | Online Article Text |
id | pubmed-10605716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106057162023-10-28 A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer Lyu, Xiao-Dan Liu, Yang Wang, Jia Wei, Yuan-Cheng Han, Yi Li, Xue Zhang, Qian Liu, Zheng-Rui Li, Zheng-Zheng Jiang, Jing-Wei Hu, Hao-Lin Yuan, Sheng-Tao Sun, Li Cancers (Basel) Article SIMPLE SUMMARY: ASCT2 is an attractive tumour metabolism target based on its critical role in cancer cell growth. The potential mechanisms of microtubule protein inhibitor C118P in breast cancer remain unknown. Identification of the potential target of C118P is essential. We evaluated the inhibitory effects of C118P on breast cancer. C118P restrained the tumour growth of MDA-MB-231 cells by inducing apoptosis, G2/M phase arrest, and autophagy. Furthermore, ASCT2 was confirmed to be a target of C118P. This is the first report to provide evidence that ASCT2 might be a candidate target of C118P in breast cancer treatment. Remarkably, this study will provide an opportunity for ASCT2 inhibition as a therapeutic strategy. ABSTRACT: Background: The microtubule protein inhibitor C118P shows excellent anti-breast cancer effects. However, the potential targets and mechanisms of C118P in breast cancer remain unknown. Methods: Real-time cellular analysis (RTCA) was used to detect cell viability. Apoptosis and the cell cycle were detected by flow cytometry. Computer docking simulations, surface plasmon resonance (SPR) technology, and microscale thermophoresis (MST) were conducted to study the interaction between C118P and alanine-serine-cysteine transporter 2 (ASCT2). Seahorse XF technology was used to measure the basal oxygen consumption rate (OCR). The effect of C118P in the adipose microenvironment was explored using a co-culture model of adipocytes and breast cancer cells and mouse cytokine chip. Results: C118P inhibited proliferation, potentiated apoptosis, and induced G2/M cell cycle arrest in breast cancer cells. Notably, ASCT2 was validated as a C118P target through reverse docking, SPR, and MST. C118P suppressed glutamine metabolism and mediated autophagy via ASCT2. Similar results were obtained in the adipocyte–breast cancer microenvironment. Adipose-derived interleukin-6 (IL-6) promoted the proliferation of breast cancer cells by enhancing glutamine metabolism via ASCT2. C118P inhibited the upregulation of ASCT2 by inhibiting the effect of IL-6 in co-cultures. Conclusion: C118P exerts an antitumour effect against breast cancer via the glutamine transporter ASCT2. MDPI 2023-10-20 /pmc/articles/PMC10605716/ /pubmed/37894450 http://dx.doi.org/10.3390/cancers15205082 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lyu, Xiao-Dan Liu, Yang Wang, Jia Wei, Yuan-Cheng Han, Yi Li, Xue Zhang, Qian Liu, Zheng-Rui Li, Zheng-Zheng Jiang, Jing-Wei Hu, Hao-Lin Yuan, Sheng-Tao Sun, Li A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer |
title | A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer |
title_full | A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer |
title_fullStr | A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer |
title_full_unstemmed | A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer |
title_short | A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer |
title_sort | novel asct2 inhibitor, c118p, blocks glutamine transport and exhibits antitumour efficacy in breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605716/ https://www.ncbi.nlm.nih.gov/pubmed/37894450 http://dx.doi.org/10.3390/cancers15205082 |
work_keys_str_mv | AT lyuxiaodan anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT liuyang anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT wangjia anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT weiyuancheng anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT hanyi anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT lixue anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT zhangqian anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT liuzhengrui anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT lizhengzheng anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT jiangjingwei anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT huhaolin anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT yuanshengtao anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT sunli anovelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT lyuxiaodan novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT liuyang novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT wangjia novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT weiyuancheng novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT hanyi novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT lixue novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT zhangqian novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT liuzhengrui novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT lizhengzheng novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT jiangjingwei novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT huhaolin novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT yuanshengtao novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer AT sunli novelasct2inhibitorc118pblocksglutaminetransportandexhibitsantitumourefficacyinbreastcancer |